

B

1637

ATTORNEY DOCKET NO.: 2003028-0049 (MIT6834 / Ariad 022A PCT/USD1)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Pomerantz et al.

Examiner: Horlick

Serial No.: 09/852,370

Art Unit: 1637

Filing Date: May 10, 2001

Title: CHIMERIC DNA-BINDING PROTEINS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TRANSMITTAL LETTER

Enclosed are the following documents:

1. Supplemental Information Disclosure Statement (4 pages);
2. Form PTO-1449 (1 page);
3. Cited Art (1 reference);
4. Check in the amount of \$180.00; and
5. Return Postcard.

If any additional fees are required to be paid or if any overpayment has been made, please charge same to Deposit Account No. 03-1721.

Respectfully submitted,

C. E. Lyon
Charles E. Lyon, D.Phil.
Registration Number 56,630

CHOATE, HALL & STEWART, LLP
Exchange Place
53 State Street
Boston, MA 02109
(617) 248-5000
(617) 248-4000
Dated: 07/01/05

3742472_1.DOC

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

7-7-05
Date

Sandra Saccoccia
Signature

Typed or Printed Name of person signing certificate



ATTORNEY DOCKET NO.: 2003028-0049 (MIT6834 / Ariad 022A PCT/USD1)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Pomerantz et al.
Serial No.: 09/852,370
Filing Date: May 10, 2001
Title: CHIMERIC DNA-BINDING PROTEINS

Examiner: Horlick
Art Unit: 1637

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

Type of Statement

The present Information Disclosure Statement is:

An *original* Information Disclosure Statement; or
 A *supplemental* Information Disclosure Statement.

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

7-7-05
Date


Signature

Sandra Saccoccia

Typed or Printed Name of person signing certificate

07/12/2005 NNGUYEN1 00000021 09852370

01 FC:1806

180.00 0P

Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

Pursuant to 37 CFR § 1.97(d), after the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *both*:

Certifies that *either*:

Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement; and

Includes herewith the fee set forth in § 1.17(p).; Please charge Deposit Account No. 03-1721.

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

A copy of each cited reference not indicated with a † is included;

Copies of references indicated with a † on the attached form PTO-1449 are not included pursuant to 37 CFR § 1.98(d) because they were previously provided to the United States Patent Office in an Information Disclosure Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the following patent application that is relied upon in the present case for an earlier effective filing date under 35 USC § 120:

Serial Number	Filing Date	Status

Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the above-identified application:

Applicant certifies that the Information Disclosure Statement *either*:

Does not contain non-English language citations;

Includes one or more translations of a non-English citation; or

Does contain non-English language citations, of which the following is a concise explanation:

Remarks

The submission of this Information Disclosure Statement should not be construed as a representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b).

The submission of this Information Disclosure Statement shall not be construed as a representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 USC § 102.


It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application; and
3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

Respectfully submitted,

Dated: *July 1, 2005*


Charles E. Lyon, D.Phil.
Registration Number: 56,630

CHOATE, HALL & STEWART, LLP
Exchange Place
53 State Street
Boston, Massachusetts 02109

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)Atty. Docket:
2003028-0049
(MIT 6834 / Ariad
022A PCT/USD1)In Re Application No.:
09/852,370Applicant: Pomerantz *et al.*Filing Date: May 10, 2001
Group: 1637

U.S. PATENT DOCUMENTS

Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass

U.S. PATENT APPLICATIONS

Examiner's Initials:	Publication Number:	Applicant:	Publication Date:	Group:	Art Unit:

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No

OTHER DOCUMENTS

Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)
	Dedera, et al., "Chimeric Homeobox Gene E2A-PBX1 Induces Proliferation, Apoptosis, and Malignant Lymphomas in Transgenic Mice", <i>Cell</i> , 74: 833-843, 1993.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.